Cholinergic status modulations in human volunteers under acute inflammation.
Cholinergic Status, the total soluble circulation capacity for acetylcholine hydrolysis, was tested for putative involvement in individual variabilities of the recruitment of immune cells in response to endotoxin challenge. Young (average age 26) and elderly (average age 70) volunteers injected with either Escherichia coli endotoxin or saline on two different occasions were first designated Enhancers and Suppressors if they showed increase or decrease, respectively, in plasma acetylcholinesterase (AChE) activity 1.5 h after endotoxin administration compared to saline. Enhancers showed significant co-increases in plasma butyrylcholinesterase (BChE) and paraoxonase (PON1) activities, accompanied by rapid recovery of lymphocyte counts. Young Enhancers alone showed pronounced post-exposure increases in the pro-inflammatory cytokine interleukin-6 (IL-6), and upregulation of the normally rare, stress-induced AChE-R variant, suggesting age-associated exhaustion of the cholinergic effects on recruiting innate immune reactions to endotoxin challenge. Importantly, IL-6 injected to young volunteers or administered in vitro to primary mononuclear blood cells caused upregulation of AChE, but not BChE or PON1, excluding it from being the sole cause for this extended response. Interestingly, Suppressors but not Enhancers showed improved post-exposure working memory performance, indicating that limited cholinergic reactions may be beneficial for cognition. Our findings establish Cholinergic Status modulations as early facilitators and predictors of individual variabilities in the peripheral response to infection.
The Institute of Life sciences, The Hebrew University of Jerusalem, Jerusalem 91904, Israel.
Keren
K
Ofek
Karen S
KS
Krabbe
Tama
T
Evron
Meir
M
Debecco
Anders R
AR
Nielsen
Helle
H
Brunnsgaad
Raz
R
Yirmiya
Hermona
H
Soreq
Bente K
BK
Pedersen
D000110:Acetylcholinesterase / Q000235:genetics / Q000378:metabolism; D000208:Acute Disease; D000328:Adult; D000368:Aged; D001288:Attention / Q000187:drug effects; D015415:Biomarkers / Q000378:metabolism; D002091:Butyrylcholinesterase / Q000378:metabolism; D002794:Choline / Q000378:metabolism*; D004731:Endotoxins / Q000494:pharmacology; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects; D007249:Inflammation / Q000378:metabolism*; D015850:Interleukin-6 / Q000008:administration & dosage / Q000494:pharmacology; D008297:Male; D008568:Memory / Q000187:drug effects; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D015854:Up-Regulation / Q000187:drug effects
D015415:Biomarkers; D004731:Endotoxins; D015850:Interleukin-6; D011994:Recombinant Proteins; D000110:Acetylcholinesterase; D002091:Butyrylcholinesterase; D002794:Choline